Wall Street Zen Upgrades Cronos Group (NASDAQ:CRON) to "Buy"

Key Points

• Wall Street Zen upgraded Cronos Group from “Hold” to “Buy. Other recent ratings were also favorable, leaving the stock with a consensus “Buy” rating and a $2.30 price target.
• Cronos reported quarterly revenue of $63.45 million and EPS of $0.04, beating analyst estimates of $51.15 million and $0.03. Revenue rose 73% year over year on an organic, constant-currency basis, with record net revenue, gross profit, and adjusted EBITDA.
• Growth was broad-based, including record sales in Canada and Germany and an 11th consecutive quarter of record net revenue in Israel; however, quarterly EPS was below the $0.07 reported a year earlier.

Cronos Group (NASDAQ:CRON - Get Free Report) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a report released on Saturday, Wall Street Zen reports.

Several other brokerages also recently issued reports on CRON. Weiss Ratings raised shares of Cronos Group from a "buy (b-)" rating to a "buy (b)" rating in a research note on Thursday, October 8th. Zacks Research raised Cronos Group from a "hold" rating to a "strong-buy" rating in a research note on Thursday, October 22nd. Finally, TD Securities reaffirmed a "buy" rating on shares of Cronos Group in a research note on Monday, September 28th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $2.30.

Cronos Group Stock Performance

Shares of CRON opened at $3.61 on Friday. Cronos Group has a 52 week low of $2.28 and a 52 week high of $3.91. The company has a 50-day simple moving average of $3.31 and a 200-day simple moving average of $2.88. The firm has a market capitalization of $1.33 billion, a P/E ratio of 30.27 and a beta of 0.96.

Cronos Group (NASDAQ:CRON - Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported $0.04 EPS for the quarter, beating the consensus estimate of $0.03 by $0.01. The business had revenue of $63.45 million for the quarter, compared to the consensus estimate of $51.15 million. Cronos Group had a return on equity of 4.85% and a net margin of 39.08%. As a group, equities analysts forecast that Cronos Group will post 0.12 earnings per share for the current year.

Institutional Trading of Cronos Group

A number of large investors have recently added to or reduced their stakes in CRON. Pure Financial Advisors LLC purchased a new stake in shares of Cronos Group during the second quarter worth approximately $28,000. OneDigital Investment Advisors LLC bought a new position in shares of Cronos Group during the 2nd quarter worth about $29,000. Two Sigma Securities LLC bought a new position in Cronos Group during the second quarter worth about $34,000. Concurrent Investment Advisors LLC raised its holdings in Cronos Group by 69.0% in the 2nd quarter. Concurrent Investment Advisors LLC now owns 19,623 shares of the company's stock valued at $55,000 after acquiring an additional 8,009 shares in the last quarter. Finally, Amundi acquired a new position in Cronos Group during the 1st quarter valued at about $54,000. Institutional investors own 8.71% of the company's stock.

Cronos Group News Summary

Here are the key news stories impacting Cronos Group this week:

• Positive Sentiment: Q3 net revenue rose 73% year over year on an organic, constant-currency basis, with the company reporting record net revenue, gross profit and adjusted EBITDA. Revenue of $63.45 million and earnings of $0.04 per share also exceeded analyst estimates of $51.15 million and $0.03, respectively. Cronos Group Reports 2026 Third Quarter Results
• Positive Sentiment: Growth was broad-based: Cronos posted record Canadian sales, a record quarter in Germany, and its 11th consecutive quarter of record net revenue in Israel. Its Spinach brand retained the top position in Canadian vapes and edibles, while the Canatolar acquisition expands its European reach. Q3 2026 Earnings Call Highlights
• Neutral Sentiment: The company said it reduced its share count, which can support per-share results, though the available reports do not quantify the effect. Cronos Group Reports 2026 Third Quarter Results
• Negative Sentiment: Despite beating estimates, Q3 earnings of $0.04 per share were below the $0.07 reported a year earlier. A separate valuation discussion also notes that the stock’s 93% three-year gain puts more focus on whether current earnings justify its valuation. Cronos Group Stock Looks Hard To Call Following Its 93% Run

About Cronos Group

Cronos Group Inc is a Canadian cannabinoid company focused on developing, producing and commercializing cannabis and cannabis-derived consumer products. The company serves adult-use and medical cannabis markets through a portfolio of brands and sells products such as dried flower, pre-rolls, vaporizers, edibles, oils and other cannabis formats, subject to applicable regulations.

Its brand portfolio has included Spinach, which is positioned primarily in the adult-use cannabis market, as well as Lord Jones and PEACE NATURALS.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.